Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

ImaginAb completes Series A financing

ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing – led by Novartis Venture Funds.

27 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Amgen announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins/

26 Mar 2012

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

Age of live donor has insignificant effect on long-term health of transplanted kidney

People with kidney failure may think that they're better off getting a new kidney from a young and spry donor, but a recent study indicates that for those over 39 years old, the age of a live donor—ranging from 18 to 64 years—has an insignificant effect on the long-term health of a transplanted kidney. The study's results appear in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

23 Mar 2012

Extreme norovirus flexibility may allow for broad antibody recognition

Twenty million Americans get sick from norovirus each year according to data released last week by the Centers for Disease Control (CDC). Often called vomiting illness, it can spread rapidly on cruise ships, and in dormitories and hospitals. Recent data from the CDC shows deaths from gastrointestinal infections have more than doubled and have become a particular threat to the elderly.

22 Mar 2012

Drexel experts available to comment for news stories about autism

Experts at Drexel University are available to comment for news stories about autism for Autism Awareness Month in April. Drexel recently established the A.J. Drexel Autism Institute, the nation's first autism center focused on public health science.

22 Mar 2012

Researchers explain how obscurins suppress breast cancer formation

A new discovery published online in The FASEB Journal may lead to a new tool to help physicians assess breast cancer risk as well as diagnose the disease. In the report, researchers from Johns Hopkins University and the University of Maryland, explain how proteins, called "obscurins," once believed to only be in muscle cells, act as "tumor suppressor genes" in the breast.

22 Mar 2012

Bone-marrow derived MSCs may reduce acute rejection rates in kidney recipients

Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.

21 Mar 2012

PEGPH20 enzyme re-expands insides of blood vessels to allow more drugs to reach tumours

Cancer Research UK scientists have shown that an enzyme can re-expand the insides of blood vessels allowing more drugs and large antibody molecules to reach pancreatic tumours, according to research published in GUT today.

21 Mar 2012

OriGene releases UltraMAB Antibodies for IHC applications

OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB brand.

21 Mar 2012

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

Researchers discover new method to identify cancer-causing translocations

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report they have discovered a method to identify cancer-causing rearrangements of genetic material called chromosomal translocations quickly, accurately, and inexpensively.

20 Mar 2012

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

GE-BAC partner to launch LambdaFabSelect bioprocess affinity resin

GE Healthcare, the healthcare business of GE and BAC BV, the leading provider of antibody-based affinity purification technology, announced today that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new and innovative affinity resin to its portfolio of technologies for the purification of antibody-based fragments.

19 Mar 2012

arGEN-X introduces NHance technology to create therapeutic antibodies

arGEN-X announces today the launch of NHance, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

19 Mar 2012

Oral BRAF inhibitor can extend survival to 16 months for patients with MM

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.

17 Mar 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.

16 Mar 2012